Lucid Diagnostics Revenue
Medical Equipment Manufacturing • 
360 Madison Ave, Floor 25, United States • 101-200 Employees
Lucid Diagnostics revenue & valuation
| Annual revenue | $4,360,000 |
| Revenue per employee | $41,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Medical Equipment Manufacturing industry and current estimated revenues | $14,000,000 |
| Total funding | $80,700,000 |
Key Contacts at Lucid Diagnostics
Michael Lautersack
Senior Area Sales Director
Lisa Krause
Sr. Director Of Employer Partnerships
Stan Lapidus
Vice-Chairman, Board Of Directors
Erica Austin
Senior Director Of First Responder Partnerships
Carlie Craig
Senior Director Strategic Partnerships
Nasim Anbarafshan Mba
Director Of Quality Assurance And Compliance
Sukanya Iyer
Senior Director, Market Access And State Government Affairs
Michelle Clapperton
National Director Of Field Clinical
Company overview
| Headquarters | 360 Madison Ave, Floor 25, New York, NY 10017, US |
| Phone number | +18885824339 |
| Website | |
| NAICS | 3391 |
| SIC | 807 |
| Founded | 2018 |
| Employees | 101-200 |
| Socials |
Lucid Diagnostics Email Formats
Lucid Diagnostics uses 2 email formats. The most common is {first name} (e.g., john@lucidchart.com), used 61.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name} | john@lucidchart.com | 61.1% |
{2char} | {2char}@lucidchart.com | 38.9% |
About Lucid Diagnostics
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device.
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Lucid Diagnostics has 49 employees across 7 departments.
Departments
Number of employees
Funding Data
Explore Lucid Diagnostics's funding history, including investment rounds, total capital raised, and key backers.
Lucid Diagnostics Tech Stack
Discover the technologies and tools that power Lucid Diagnostics's digital infrastructure, from frameworks to analytics platforms.
CDN
CDN
JavaScript libraries
Tag managers
Webmail
Miscellaneous
Security
Miscellaneous
Page builders
Analytics
Miscellaneous
Font scripts
Switzerland
Namibia
Spain
MexicoFrequently asked questions
4.8
40,000 users
